FDA grants accelerated approval to Ocaliva™ (obeticholic acid) for treatment of PBC
Intercept Pharma announced the FDA has granted accelerated approval to Ocaliva (obeticholic acid) for treatment of primary biliary cholangitis, in combination with ursodeoxycholic in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. May 27, 2016